Skip to content

Safety Study of Feeding With Ginger Extract in Acute Respiratory Distress Syndrome

Effect of Enteral Feeding With Ginger Extract in Acute Respiratory Distress Syndrome

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00958685
Enrollment
32
Registered
2009-08-13
Start date
2007-01-31
Completion date
2009-01-31
Last updated
2009-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome

Keywords

ginger extract, ARDS, enteral feeding, mechanical ventilation, ICU

Brief summary

An enteral diet supplemented with ginger extract in acute respiratory distress syndrome (ARDS) patients may be beneficial for gas exchange and could decrease duration of mechanical ventilation and length of stay in intensive care unit (ICU).

Detailed description

Rationale: Clinical ARDS occurs primarily as the result of inflammatory injury to the alveoli producing diffuse alveolar damage. Objective: To evaluate the effects of an enteral diet enriched with ginger extract on inflammatory factors, respiratory profile and outcome of patients with ARDS. Methods: In this single center, randomized, controlled double blind study, 32 patients with ARDS were randomized to receive a high protein enteral diet enriched with ginger extract or placebo. Measurements and Main Results: Serum levels of IL-1, IL-6, TNF-α and LTB-4, oxygenation, measured as PaO2/FiO2, static compliance measured on days 0, 5 and 10. Patients fed enteral diet enriched with ginger extract had significantly lower serum levels of IL-1, IL-6, TNF-α and LTB-4 on days 5 and 10 compared to control group (P\<0.05). Significant improvement in oxygenation was observed on day 5 (P=0.02) and 10 (P=0.003) in ginger extract group compared to control group. Static compliance was also increased significantly on day 5 (P=0.01) in ginger extract group compared to control group. A significant difference was found in duration of mechanical ventilation (P0.02) and length of ICU stay (P=0.04) in favor of ginger extract group. We did not find any difference in barotraumas, organ failure and mortality between the study groups. Conclusions: An enteral diet supplemented with ginger extract in ARDS patients may be beneficial for gas exchange and could decrease duration of mechanical ventilation and length of stay in ICU.

Interventions

DIETARY_SUPPLEMENTginger

Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo

DIETARY_SUPPLEMENTplacebo

Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo

Sponsors

Shahid Beheshti University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Required positive pressure ventilation via endotracheal tube or tracheostomy and were on enteral nutrition support. * Also they had to have an acute onset of significantly impaired oxygenation with a PaO2 to FiO2 ratio equal or less than 200, bilateral pulmonary infiltrates on frontal chest radiograph and no clinical evidence of left atrial hypertension according to the American-European Consensus Conference on ARDS . * Patients had to be enrolled within 48 hours of developing these criteria.

Exclusion criteria

* Age younger than 18 years * Participation in other interventional trials in the previous 30 days * Neurological conditions that could impair weaning from ventilatory support, * Severe chronic respiratory disease * Pregnancy * Lactation * Active bleeding * Head trauma * Intracranial hemorrhage * Peptic ulcer * HIV infection * Food allergy * Morbid obesity * Malignancy or other irreversible conditions for which 6 months mortality was estimated to be 50% or more and who were receiving nonsteroidal anti inflammatory drugs or ketoconazole.

Design outcomes

Primary

MeasureTime frame
changes in oxygenation, respiratory mechanics and serum inflammatory factors21 days
oxygenation21 days

Secondary

MeasureTime frame
the number of organ failure free days, the occurrence of barotraumas, the number of ventilator free days, the number of ICU free days and ICU mortality.after intervention

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026